Entra Health has recently announced the launch of Entra360, a novel solution for easily and effectively implementing wireless biometric data. Entra360 is a particularly innovative solution for both the payer or provider, as well as the COPD clinical research market. Entra360 is one of several efforts the company is making to provide easy-to-implement solutions to allow remote patient monitoring and cloud-based analytics.
Entra360 integrates with the firms’s MyHealthPoint real-time online data collection network, which has been approved by the FDA as a 510K Class II solution. The technology also interfaces with MyGlucoHealth, the first FDA approved wireless blood glucose meter. MyGlucoHealth is now the standard solution to bring together glucose data in clinical trials and has been approved in 50 countries. It can store and report a large spectrum of data such as blood glucose values, blood pressure, weight, ECG and activity monitoring data; it can also include additional biometric inputs from other devices produced by multiple worldwide manufacturers.
“Entra360 was built on the most trusted, proven and versatile interconnection architecture in the industry. By design, it is universally compatible with nearly every EHR/EMR system. The Internet web service APIs, Android/WinPhone Entra Listener Apps and ecosystem interfaces offer customers the ability to leverage the platform and device connectivity for their own application or to use the MyHealthPoint viewing and reporting structure through web or mobile devices within a direct clinical environment or for double blind masking in clinical research,” said Entra Health’s CEO, Richard C. Strobridge. “Entra360 is currently being used in research studies related to chronic illnesses such as heart disease, diabetes, sleep disorders, COPD and hypertension in more than 75 countries around the world. Approval of investigational new drugs (IND) depends on accurate, timely and secure data collection from trial participants. Entra360 technology quietly monitors not just the testing results of patients, but also the patterns of their testing. Using this information and automated tools, Entra360 can set up reminders to encourage patients to test more frequently, as well as to notify investigators and clinicians when testing patterns fluctuate.”
In addition, Entra360 encrypts all personal information that is stored in the system, with privacy passwords controlled by the individual, caregiver or clinician. The company believes that the collection of this data might assist in the clarification and establishment of clinical trial and treatment strategies to improve overall patient care for diseases such as COPD.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?